Ultragenyx Pharmaceutical (RARE) Other Non-Current Liabilities (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Other Non-Current Liabilities data on file, last reported at $42.0 million in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $42.0 million, up 145.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $42.0 million (up 145.28% YoY), and the FY2025 annual result was $44.0 million, up 158.82% from the prior year.
• Other Non-Current Liabilities retreated to $42.0 million in Q1 2026 per RARE's latest filing, from $44.0 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $881.0 million in Q2 2023 and troughed at $3.8 million in Q2 2022.
• A 5-year average of $349.1 million and a median of $42.0 million in 2026 frame the typical range for Other Non-Current Liabilities.
• On a YoY basis, Other Non-Current Liabilities climbed as much as 59575.46% in 2022 and fell as far as 98.9% in 2022.
• A 5-year view of Other Non-Current Liabilities shows it stood at $875.4 million in 2022, then retreated by 1.5% to $862.3 million in 2023, then tumbled by 98.03% to $17.0 million in 2024, then soared by 158.82% to $44.0 million in 2025, then retreated by 4.55% to $42.0 million in 2026.
• Business Quant data shows RARE's Other Non-Current Liabilities at $42.0 million in Q1 2026, $44.0 million in Q4 2025, and $763.7 million in Q3 2025.